Camilo Jimenez

Apr 9, 2024 | thelancet.com | Matthew Campbell |Vania Balderrama-Brondani |Hormonal Disorders |Camilo Jimenez

Summary Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma.